암 악액질 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 6.2%의 성장률(CAGR)로 33억 3,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 악액질 관리에 대한 인식 증가, 노인 인구 증가, 새로운 치료법 채택 확대, 의료비 지출 증가, 정부 지원 정책 등에 기인하는 것으로 분석됩니다. 예측 기간 동안 주요 동향으로는 연구개발 노력 증가, 치료 옵션 확대, 진단율 향상, 새로운 치료법 채택, 지지요법 전략의 발전 등이 있습니다.
암 유병률 증가는 암 악액질 시장의 성장을 견인할 것으로 예측됩니다. 암은 비정상적인 세포의 통제할 수 없는 증식을 특징으로 하는 병태로, 종양 형성 및 정상적인 신체 기능의 붕괴를 초래합니다. 암 발병률 증가는 생활습관의 변화, 환경적 영향, 인구 고령화, 유전적 소인, 조기 발견을 가능하게 하는 진단 기술의 향상, 더 많은 사람들이 의료 서비스를 받으려는 사회적 인식 증가 등 여러 가지 요인에 기인합니다. 의료 기술의 발전과 암 및 관련 합병증에 대한 이해도가 높아짐에 따라 암 악액질 진단 및 보고 빈도가 증가하고 있습니다. 의료진은 악액질 증상을 식별하는 데 익숙해지고 있으며, 이는 조기 치료 개입을 가능케 하고 있습니다. 예를 들어, 2023년 12월 호주 통계청은 2022년 호주 인구의 약 1.8%인 45만 6,200명이 암 진단을 받았다고 보고했습니다. 또한 미국 연방 기관인 국립암연구소는 2024년 미국에서 200만 1,140명의 암 환자가 새로 진단받고 61만 1,720명이 사망할 것으로 예상하고 있으며, 2022년에는 전 세계적으로 약 2,000만 명이 새로 암 진단을 받고 970만 명이 사망할 것으로 예상하고 있습니다.에는 신규 암 환자 수는 연간 2,990만 명, 암 관련 사망자는 1,530만 명에 달할 것으로 예측됩니다. 이처럼 암 유병률 증가는 암 악액질 시장의 성장을 크게 촉진하고 있습니다.
암 악액질 시장의 주요 업체들은 암 악액질을 관리하고 환자의 체중, 근육량, 전반적인 삶의 질을 개선하기 위한 표적 솔루션을 제공하기 위해 단클론항체와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 악액질에 대한 단일클론항체는 근육과 체중 감소를 유발하는 요인을 표적으로 삼아 이를 억제하는 방식으로 작용합니다. 예를 들어, 2024년 9월 미국 제약사 Pfizer Inc.는 암 악액질 환자를 대상으로 한 GDF-15를 표적으로 하는 단일클론항체 Ponsegromab의 2상 임상 2상 시험의 좋은 결과를 보고했습니다. 이 시험에서 근육량, 식욕, 신체활동성 개선과 함께 체중이 유의하게 증가했으며, 400mg 투여 시 가장 두드러진 결과를 보였습니다. 이러한 유망한 결과를 바탕으로 화이자는 폰세글로맙의 암 악액질 치료제로서의 가능성을 더욱 모색하기 위해 2025년에 등록 가능한 임상을 시작할 예정입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 암 악액질 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 암 악액질 시장 : 성장률 분석
- 세계의 암 악액질 시장 실적 : 규모와 성장, 2019-2024
- 세계의 암 악액질 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 암 악액질 전체 시장(TAM)
제6장 시장 세분화
- 세계의 암 악액질 시장 : 치료제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 프로게스토겐
- 코르티코스테로이드
- 병용 요법
- 기타 치료제
- 세계의 암 악액질 시장 : 작용기전별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 식욕 증진제
- 감량 안정제
- 기타 작용기전
- 세계의 암 악액질 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 매점
- 소매 약국
- 온라인 약국
- 세계의 암 악액질 시장 : 프로게스토겐 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- Megestrol Acetate
- Medroxyprogesterone Acetate
- Hydroxyprogesterone Caproate
- 세계의 암 악액질 시장 : 코르티코스테로이드 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- Dexamethasone
- Prednisolone
- Methylprednisolone
- 세계의 암 악액질 시장 : 병용 요법 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- Progestogens + Corticosteroids
- Progestogens + Anabolic Agents
- Corticosteroids + Anabolic Agents
- 세계의 암 악액질 시장 : 기타 치료제 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 동화물질(Anabolic Agents)
- 식욕 증진제
- 항염증제
- 식이보충제
제7장 지역별/국가별 분석
- 세계의 암 악액질 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 암 악액질 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 암 악액질 시장 : 경쟁 구도
- 암 악액질 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
- Bristol Myers Squibb Company
- AstraZeneca plc
- Novartis International AG
- Fresenius SE & Co. KGaA
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Daiichi Sankyo Company Limited
- Sun Pharmaceutical Industries Ltd.
- Perrigo Company plc
- Kyowa Kirin Co. Ltd.
- Hikma Pharmaceuticals plc
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 암 악액질 시장(2029년) : 새로운 기회를 제공하는 국가
- 암 악액질 시장(2029년) : 새로운 기회를 제공하는 부문
- 암 악액질 시장(2029년) : 성장 전략
제36장 부록
LSH
Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. This multifactorial condition arises from a combination of factors, including inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient's quality of life, impair their ability to tolerate cancer treatments, and reduce overall survival.
The main therapeutics for cancer cachexia include progestogens, corticosteroids, combination therapies, and others. Progestogens, a type of medication often used in treating cancer cachexia, work by mimicking the effects of natural progesterone hormones in the body, potentially helping to increase appetite and muscle mass in patients. These treatments operate through various mechanisms, such as appetite stimulation and weight loss stabilization, and are distributed via hospital stores, retail pharmacies, and online pharmacies.
The cancer cachexia market research report is one of a series of new reports from The Business Research Company that provides cancer cachexia market statistics, including cancer cachexia industry global market size, regional shares, competitors with a cancer cachexia market share, detailed cancer cachexia market segments, market trends and opportunities, and any further data you may need to thrive in the cancer cachexia industry. This cancer cachexia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cancer cachexia market size has grown strongly in recent years. It will grow from $2.47 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to an improved understanding of cancer biology, the prevalence of cancer, an increased aging population, a greater focus on patient-centered care, expanding treatment options, and growing awareness among healthcare providers.
The cancer cachexia market size is expected to see strong growth in the next few years. It will grow to $3.33 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness about cachexia management, expanding geriatric population, growing adoption of novel therapeutic approaches, rising healthcare expenditure, and favorable government initiatives. Major trends in the forecast period include increasing research and development efforts, expanding therapeutic options, improved diagnosis rates, adoption of novel treatment modalities, and advancements in supportive care strategies.
The growing prevalence of cancer is expected to drive the expansion of the cancer cachexia market. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells, leading to tumor formation and disruption of normal bodily functions. The increasing incidence of cancer is attributed to several factors, including lifestyle changes, environmental influences, aging populations, genetic predisposition, improved diagnostic techniques allowing for earlier detection, and greater public awareness, leading more individuals to seek medical attention. Advances in medical technology and a deeper understanding of cancer and its associated complications are contributing to more frequent diagnoses and reporting of cancer cachexia. Healthcare providers are becoming more adept at identifying the symptoms of cachexia, enabling earlier treatment interventions. For example, in December 2023, the Australian Bureau of Statistics reported that approximately 1.8% of the Australian population, or 456,200 individuals, were diagnosed with cancer in 2022. Additionally, the National Cancer Institute, a US-based federal agency, projected that 2,001,140 new cancer cases would be diagnosed in the U.S. in 2024, with 611,720 expected deaths. In 2022, there were nearly 20 million new cases and 9.7 million cancer-related deaths globally. By 2040, the number of new cancer cases is expected to reach 29.9 million annually, with cancer-related deaths rising to 15.3 million. Thus, the increasing prevalence of cancer is significantly driving the growth of the cancer cachexia market.
Key players in the cancer cachexia market are focusing on developing innovative treatments, such as monoclonal antibodies, to provide targeted solutions for managing cancer cachexia and improving patients' body weight, muscle mass, and overall quality of life. Monoclonal antibodies for cachexia work by targeting and inhibiting the factors responsible for muscle and weight loss. For example, in September 2024, Pfizer Inc., a US-based pharmaceutical company, reported the positive results from its Phase 2 trial of Ponsegromab, a monoclonal antibody aimed at targeting GDF-15 in cancer cachexia patients. The study showed a significant increase in body weight, along with improvements in muscle mass, appetite, and physical activity, with the 400 mg dose yielding the most notable results. Following these encouraging outcomes, Pfizer plans to launch registration-enabling studies in 2025 to further explore Ponsegromab's potential as a treatment for cancer cachexia.
In January 2023, LG Chem Ltd., a South Korean chemical company, acquired AVEO Oncology for an undisclosed amount. This acquisition aims to diversify LG Chem's product portfolio and enhance its capabilities in drug development, commercialization, and acquisitions, thereby accelerating its progress toward delivering cutting-edge cancer treatments. AVEO Oncology, a US-based biopharmaceutical company, provides a potential treatment for cancer cachexia.
Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.
North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cancer cachexia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cancer cachexia market consists of revenues earned by entities by providing services such as nutritional counseling, physical therapy, and exercise training. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer cachexia market also includes sales of anabolic steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral nutritional supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cancer Cachexia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cancer cachexia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cancer cachexia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer cachexia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics
- 2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions
- 3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies
- Subsegments:
- 1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate
- 2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone
- 3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents
- 4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements
- Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi SA
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Cancer Cachexia Market Characteristics
3. Cancer Cachexia Market Trends And Strategies
4. Cancer Cachexia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Cancer Cachexia Growth Analysis And Strategic Analysis Framework
- 5.1. Global Cancer Cachexia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Cancer Cachexia Market Growth Rate Analysis
- 5.4. Global Cancer Cachexia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Cancer Cachexia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Cancer Cachexia Total Addressable Market (TAM)
6. Cancer Cachexia Market Segmentation
- 6.1. Global Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Progestogens
- Corticosteroids
- Combination Therapies
- Other Therapeutics
- 6.2. Global Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Appetite Stimulators
- Weight Loss Stabilizers
- Other Mechanisms Of Actions
- 6.3. Global Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Stores
- Retail Pharmacy Stores
- Online Pharmacies
- 6.4. Global Cancer Cachexia Market, Sub-Segmentation Of Progestogens, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Megestrol Acetate
- Medroxyprogesterone Acetate
- Hydroxyprogesterone Caproate
- 6.5. Global Cancer Cachexia Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dexamethasone
- Prednisolone
- Methylprednisolone
- 6.6. Global Cancer Cachexia Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Progestogens + Corticosteroids
- Progestogens + Anabolic Agents
- Corticosteroids + Anabolic Agents
- 6.7. Global Cancer Cachexia Market, Sub-Segmentation Of Other Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anabolic Agents
- Appetite Stimulants
- Anti-inflammatory Drugs
- Nutritional Supplements
7. Cancer Cachexia Market Regional And Country Analysis
- 7.1. Global Cancer Cachexia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Cancer Cachexia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Cancer Cachexia Market
- 8.1. Asia-Pacific Cancer Cachexia Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Cancer Cachexia Market
- 9.1. China Cancer Cachexia Market Overview
- 9.2. China Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Cancer Cachexia Market
- 10.1. India Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Cancer Cachexia Market
- 11.1. Japan Cancer Cachexia Market Overview
- 11.2. Japan Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Cancer Cachexia Market
- 12.1. Australia Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Cancer Cachexia Market
- 13.1. Indonesia Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Cancer Cachexia Market
- 14.1. South Korea Cancer Cachexia Market Overview
- 14.2. South Korea Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Cancer Cachexia Market
- 15.1. Western Europe Cancer Cachexia Market Overview
- 15.2. Western Europe Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Cancer Cachexia Market
- 16.1. UK Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Cancer Cachexia Market
- 17.1. Germany Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Cancer Cachexia Market
- 18.1. France Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Cancer Cachexia Market
- 19.1. Italy Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Cancer Cachexia Market
- 20.1. Spain Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Cancer Cachexia Market
- 21.1. Eastern Europe Cancer Cachexia Market Overview
- 21.2. Eastern Europe Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Cancer Cachexia Market
- 22.1. Russia Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Cancer Cachexia Market
- 23.1. North America Cancer Cachexia Market Overview
- 23.2. North America Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Cancer Cachexia Market
- 24.1. USA Cancer Cachexia Market Overview
- 24.2. USA Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Cancer Cachexia Market
- 25.1. Canada Cancer Cachexia Market Overview
- 25.2. Canada Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Cancer Cachexia Market
- 26.1. South America Cancer Cachexia Market Overview
- 26.2. South America Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Cancer Cachexia Market
- 27.1. Brazil Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Cancer Cachexia Market
- 28.1. Middle East Cancer Cachexia Market Overview
- 28.2. Middle East Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Cancer Cachexia Market
- 29.1. Africa Cancer Cachexia Market Overview
- 29.2. Africa Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Cancer Cachexia Market Competitive Landscape And Company Profiles
- 30.1. Cancer Cachexia Market Competitive Landscape
- 30.2. Cancer Cachexia Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
31. Cancer Cachexia Market Other Major And Innovative Companies
- 31.1. Bristol Myers Squibb Company
- 31.2. AstraZeneca plc
- 31.3. Novartis International AG
- 31.4. Fresenius SE & Co. KGaA
- 31.5. GlaxoSmithKline plc
- 31.6. Takeda Pharmaceutical Company
- 31.7. Eli Lilly and Company
- 31.8. Boehringer Ingelheim International GmbH
- 31.9. Teva Pharmaceutical Industries Ltd.
- 31.10. Astellas Pharma Inc.
- 31.11. Daiichi Sankyo Company Limited
- 31.12. Sun Pharmaceutical Industries Ltd.
- 31.13. Perrigo Company plc
- 31.14. Kyowa Kirin Co. Ltd.
- 31.15. Hikma Pharmaceuticals plc
32. Global Cancer Cachexia Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Cancer Cachexia Market
34. Recent Developments In The Cancer Cachexia Market
35. Cancer Cachexia Market High Potential Countries, Segments and Strategies
- 35.1 Cancer Cachexia Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Cancer Cachexia Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Cancer Cachexia Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
